Market Overview:
The global next generation cancer diagnostics market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as the increasing incidence of cancer, technological advancements in diagnostic methods, and rising demand for personalized medicine. The next generation sequencing segment is expected to account for the largest share of the global next generation cancer diagnostics market in 2018. This segment is projected to grow at a CAGR of 11.5% during the forecast period from 2018 to 2030.
Product Definition:
The term "next generation cancer diagnostics" refers to cutting-edge technologies and techniques for detecting and diagnosing cancer. These can include advanced imaging techniques, biomarker detection methods, and genetic sequencing. Next generation cancer diagnostics are important because they can provide more accurate diagnoses, helping to ensure that patients receive the most effective treatment possible.
Next Generation Sequencing:
Next Generation Sequencing (NGS) is a high throughput sequencing method that enables the determination of many genetic changes simultaneously. It has been used extensively for the analysis of human genome and it's associated diseases. NGS allows comprehensive mapping of all disease-associated mutations, which has accelerated cancer diagnostics research.
qPCR & Multiplexing:
The Next Generation Cancer Diagnostics (NGCD) market is expected to witness significant growth over the forecast period. One of the major drivers for this market is increasing prevalence of cancer and growing demand for early diagnosis. According to WHO, it was estimated that globally, cancer will account for about 8th leading cause of deaths by 2020.
Application Insights:
The others segment held the largest share of the global next generation cancer diagnostics market in 2017. This is due to factors such as an increase in demand for companion diagnostic tests across various settings, growing investments by private players and government support for initiatives related to oncology diagnostics. For instance, a joint initiative of industry partners, National Cancer Center Japan and Ministry of Health, Labour & Welfare (NCCJ/MHLW) has resulted in introduction of new molecular diagnostic services for lung cancer patients.
In addition, collaborations among key companies are expected to enhance product offerings during the forecast period. For instance, Biodesix LDT II collaboration with Thermo Fisher Scientific involves development and commercialization of liquid biopsy companion diagnostic test based on Roche's proprietary Nucletome platform that enables detection limit less than 10 tumor cells per millilitre blood sample drawn from the patient.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, increased government funding for cancer research and development of new diagnostic technologies, and high prevalence of cancer in this region. For instance, as per statistics published by American Cancer Society in 2018, around 1.7 million people will be diagnosed with invasive bladder cancers and over 160 thousand people will die from it during the forecast period – making it as the second most commonly occurring cause of death among men (after lung cancer). Thus a large number of population suffering from various symptoms associated with GNGT makes it necessary to adopt these tests for early diagnosis which is further fueling growth in this region.
Asia Pacific is expected to grow at a lucrative rate over the forecast period owing to increasing R&D investments by various companies coupled with rising healthcare expenditure by governments across emerging countries such as China & India thus making them potential markets for these diagnostics services providers operating within GNGT space.
Growth Factors:
- Increasing incidence of cancer: The global incidence of cancer is increasing at an alarming rate. This is primarily due to the aging population and the rising prevalence of lifestyle-related cancers. According to the World Health Organization (WHO), there were 14 million new cases of cancer in 2012, and this number is expected to rise to 21 million by 2030. This presents a huge opportunity for Next Generation Cancer Diagnostics market players as they seek to develop innovative diagnostic technologies that can help in early detection and treatment of cancer.
- Advances in technology: Technological advances are playing a key role in the development of Next Generation Cancer Diagnostics market products and services. For instance, next-generation sequencing (NGS) technology has revolutionized DNA sequencing, making it faster, more accurate, and less expensive than traditional methods such as Sanger sequencing. This has led to the development of novel diagnostic tests that can detect genetic mutations associated with various types of cancers at an early stage.
Scope Of The Report
Report Attributes
Report Details
Report Title
Next Generation Cancer Diagnostics Market Research Report
By Type
Next Generation Sequencing, qPCR & Multiplexing, DNA Microarrays, Others
By Application
Hospitals, Clinics, Others
By Companies
Cepheid, Koninklijke Philips N.V, F. Hoffmann-La Roche Ltd, Qiagen, Novartis AG, Abbott, Thermo Fisher Scientific, Opko Health, Myriad Genetics, Agilent Technologies, GE Healthcare, PerkinElmer, Genomic Health, Illumina, Hologic, Almac Group, Janssen Global Services, Sysmex Corporation
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Next Generation Cancer Diagnostics Market Report Segments:
The global Next Generation Cancer Diagnostics market is segmented on the basis of:
Types
Next Generation Sequencing, qPCR & Multiplexing, DNA Microarrays, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Cepheid
- Koninklijke Philips N.V
- F. Hoffmann-La Roche Ltd
- Qiagen
- Novartis AG
- Abbott
- Thermo Fisher Scientific
- Opko Health
- Myriad Genetics
- Agilent Technologies
- GE Healthcare
- PerkinElmer
- Genomic Health
- Illumina
- Hologic
- Almac Group
- Janssen Global Services
- Sysmex Corporation
Highlights of The Next Generation Cancer Diagnostics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Next Generation Sequencing
- qPCR & Multiplexing
- DNA Microarrays
- Others
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Next Generation Cancer Diagnostics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Next Generation Cancer Diagnostics is a company that provides diagnostic tools for cancer patients. These tools include tests to help identify the type of cancer, how advanced it is, and whether or not it has spread. Next Generation also offers treatments and therapies for cancers that have been identified.
Some of the key players operating in the next generation cancer diagnostics market are Cepheid, Koninklijke Philips N.V, F. Hoffmann-La Roche Ltd, Qiagen, Novartis AG, Abbott, Thermo Fisher Scientific, Opko Health, Myriad Genetics, Agilent Technologies, GE Healthcare, PerkinElmer, Genomic Health, Illumina, Hologic, Almac Group, Janssen Global Services, Sysmex Corporation.
The next generation cancer diagnostics market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Next Generation Cancer Diagnostics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Next Generation Cancer Diagnostics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Next Generation Cancer Diagnostics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Next Generation Cancer Diagnostics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Next Generation Cancer Diagnostics Market Size & Forecast, 2018-2028
4.5.1 Next Generation Cancer Diagnostics Market Size and Y-o-Y Growth
4.5.2 Next Generation Cancer Diagnostics Market Absolute $ Opportunity
Chapter 5 Global Next Generation Cancer Diagnostics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Next Generation Cancer Diagnostics Market Size Forecast by Type
5.2.1 Next Generation Sequencing
5.2.2 qPCR & Multiplexing
5.2.3 DNA Microarrays
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Next Generation Cancer Diagnostics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Next Generation Cancer Diagnostics Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Next Generation Cancer Diagnostics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Next Generation Cancer Diagnostics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Next Generation Cancer Diagnostics Analysis and Forecast
9.1 Introduction
9.2 North America Next Generation Cancer Diagnostics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Next Generation Cancer Diagnostics Market Size Forecast by Type
9.6.1 Next Generation Sequencing
9.6.2 qPCR & Multiplexing
9.6.3 DNA Microarrays
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Next Generation Cancer Diagnostics Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Next Generation Cancer Diagnostics Analysis and Forecast
10.1 Introduction
10.2 Europe Next Generation Cancer Diagnostics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Next Generation Cancer Diagnostics Market Size Forecast by Type
10.6.1 Next Generation Sequencing
10.6.2 qPCR & Multiplexing
10.6.3 DNA Microarrays
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Next Generation Cancer Diagnostics Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Next Generation Cancer Diagnostics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Next Generation Cancer Diagnostics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Next Generation Cancer Diagnostics Market Size Forecast by Type
11.6.1 Next Generation Sequencing
11.6.2 qPCR & Multiplexing
11.6.3 DNA Microarrays
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Next Generation Cancer Diagnostics Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Next Generation Cancer Diagnostics Analysis and Forecast
12.1 Introduction
12.2 Latin America Next Generation Cancer Diagnostics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Next Generation Cancer Diagnostics Market Size Forecast by Type
12.6.1 Next Generation Sequencing
12.6.2 qPCR & Multiplexing
12.6.3 DNA Microarrays
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Next Generation Cancer Diagnostics Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Next Generation Cancer Diagnostics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Next Generation Cancer Diagnostics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Next Generation Cancer Diagnostics Market Size Forecast by Type
13.6.1 Next Generation Sequencing
13.6.2 qPCR & Multiplexing
13.6.3 DNA Microarrays
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Next Generation Cancer Diagnostics Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Next Generation Cancer Diagnostics Market: Competitive Dashboard
14.2 Global Next Generation Cancer Diagnostics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Cepheid
14.3.2 Koninklijke Philips N.V
14.3.3 F. Hoffmann-La Roche Ltd
14.3.4 Qiagen
14.3.5 Novartis AG
14.3.6 Abbott
14.3.7 Thermo Fisher Scientific
14.3.8 Opko Health
14.3.9 Myriad Genetics
14.3.10 Agilent Technologies
14.3.11 GE Healthcare
14.3.12 PerkinElmer
14.3.13 Genomic Health
14.3.14 Illumina
14.3.15 Hologic
14.3.16 Almac Group
14.3.17 Janssen Global Services
14.3.18 Sysmex Corporation
